Brief: Genscript Biotech Reports HY Revenue Increasing 32.7%
31/08/2022 14:48
Aug 31 (Reuters) - Genscript Biotech Corp 1548.HK :
* HY REVENUE US$304.7 MILLION, INCREASE OF 32.7%
* HY LOSS ATTRIBUTABLE US$131.2 MILLION VERSUS LOSS US$91.1
MILLION
Further company coverage: 1548.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genscript Biotech
See all newsBrief: Genscript Launches Life Sciences Startup Pitchfest With Nvidia For Biotech Innovation
GenScript Biotech extends gain to hit near 5-year peak on Eli Lilly deal
GenScript Biotech hits near 5-year high on Eli Lilly collaboration
Brief: ProBio & Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO Solutions
HK-listed GenScript Biotech drops on discounted share sale